Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» AstraZeneca, Bristol resubmit NDA for diabetes therapy dapagliflozin
AstraZeneca, Bristol resubmit NDA for diabetes therapy dapagliflozin
AstraZeneca, Bristol resubmit NDA for diabetes therapy dapagliflozin
Submitted by
admin
on July 25, 2013 - 11:16am
Source:
Fierce Biotech
News Tags:
diabetes
Dapagliflozin
Bristol-Myers Squibb
AstraZeneca
Headline:
AstraZeneca, Bristol resubmit NDA for diabetes therapy dapagliflozin
Do Not Allow Advertisers to Use My Personal information
